Skip to main content

Table 1 Baseline characteristics of the studies in the meta-analysis

From: Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis

Studies (reference) Year Country Treatment Sample size (male, n) Mean/median ages (years) Vascular invasion (yes) Differentiation (I,II/III,IV,n)
Shirakawal [18] 2009 Japan SR 107(85) 63.6/60.2 57 12/95
Yorita [19] 2010 Japan SR 194(142) NA 108 179/15
Su [20] 2012 China SR 61(55) 48.0 NA NA
Yu [21] 2012 Taiwan SR 100(90) 51.39 23 NA
Wang [23] 2012 China LT 31(29) 49 16 6/25
Chen [24] 2013 Japan SR 55(36) 65.5 /63.5 NA NA
Fu [25] 2013 China SR 160(140) 50.2 30 123/37
Liang [26] 2013 China SR 362(324) 43-50 53 NA
Studies (Reference) Tumor stage (I, II/ III, IV, n) Follow- up Mean/ median (months) Outcome indexes Multi- variate analysis Patients with High GPC3 Study quality (Points) "high" GPC3 cut- off level
Shirakawal [18] 92/15 42 OS/DFS Yes 87 8/9 >10 %
Yorita [19] 82/112 31.2 OS/DFS Yes 97 7/9 ≥20 %
Su [20] 45/16 NA OS/DFS Yes 32 5/9 >10 %
Yu [21] NA 66.5 DFS NA NA 5/9 +3*
Wang [23] 12/19 24 DFS NA 20 5/9 >10 %
Chen [24] NA 66 OS/DFS yes 28 6/9 >10 %
Fu [25] NA 34.5 OS/DFS yes 109 8/9 >25 %
Liang [26] NA 34.5 OS NA 228 6/9 >0 %
Studies (Reference) Antibody type Detection method Evaluation method GPC3 staining
Shirakawal [18] Mouse Monoclonal antibody IHC Positive area Cytoplasm membrane
Yorita [19] Monoclonal antibody IHC: Histofine Her2 kit Positive area Cytoplasm membrane
Su [20] Mouse Monoclonal antibody IHC: Chemmate EnVision/Mo&Rb detection kit Positive area and intensity Cytoplasm membrane
Yu [21] NA IHC NA Cytoplasm membrane
Wang [23] Monoclonal antibody IHC Positive area Cytoplasm membrane
Chen [24] Rabbit monoclonal antibody IHC Positive area cytoplasm peri- canalicular
Fu [25] Mouse Monoclonal antibody IHC Percentage of positive cells Cytoplasm membrane
Liang [26] NA IHC: two-step protocol (DakoCytomation, Glostrup, Denmar) TMAJ Image application Cytoplasm membrane
  1. SR, surgical resection; LT, livertransplantation; NA, not available; IHC, immunohistochemistry; OS, overall survival; DFS, disease-free survival.
  2. Tumor vascular invasion was defined as presence of either macro- or microscopic vascular invasion (including portal vein invasion, etc.).
  3. High glypican-3 cut-off level was scored according to the percentage of positive tumor cells by immunohistochemical staining.
  4. *The expression level was scored on a scale from -3 (underexpression) to +3 (overexpression).